Kamal Kabakibou, MD
Pain Management · Atlanta, GANPI 1356427850
Payments from drug & device makers
Across 629 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$2K
- Redhill Biopharma Inc.$2K
- AbbVie$2K
- Amgen$1K
- Collegium Pharmaceutical, Inc.$807
- Biohaven Pharmaceutical Holding Company Ltd.$601
- plus $8K from 53 others
What the payments were for
- Consulting fees$2,86018%
- Travel & lodging$5774%
- Food & beverage$12,20677%
- Education$2321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOVANTIK$1,660
- NURTEC ODT$1,583
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$366
- IFUSE IMPLANT SYSTEM$273
- Senza$233
- UBRELVY$126
- Omnia$126
- iFuse Implant$106
- INTELLIS ADAPTIVESTIM$106
- PROCLAIM$105
How this compares
Too few pain management providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,007 | $171,507 |
| BelbucaBuprenorphine Hcl | 175 | $163,044 |
| RelistorMethylnaltrexone Bromide | 20 | $89,724 |
| Xtampza ErOxycodone Myristate | 181 | $88,217 |
| Nurtec OdtRimegepant Sulfate | 52 | $79,976 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,850 | $47,834 |
| LinzessLinaclotide | 76 | $45,400 |
| BelsomraSuvorexant | 82 | $36,755 |
| OxycontinOxycodone Hcl | 91 | $36,267 |
| Aimovig AutoinjectorErenumab-Aooe | 48 | $34,766 |
| NucyntaTapentadol Hcl | 24 | $28,401 |
| MovantikNaloxegol Oxalate | 55 | $27,165 |
| ZtlidoLidocaine | 32 | $26,724 |
| Buprenorphine | 75 | $24,451 |
| Diclofenac Sodium | 209 | $20,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $807 | $279,661380 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $497 | $89,72420 claims |
| PfizerNurtec Odt | $262 | $79,97652 claims |
| AbbVieLinzess, Ubrelvy | $1,760 | $61,08989 claims |
| MerckBelsomra | $195 | $36,75582 claims |
| Redhill Biopharma Inc.Movantik | $1,774 | $27,16555 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $164 | $26,72432 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $108 | $15,84521 claims |
| Shionogi IncSymproic | $12 | $13,74417 claims |
| Eisai Inc.Dayvigo | $260 | $12,62138 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $101 | $9,36715 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $192 | $7,40215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other pain management in Atlanta
- Shannon WheatAtlanta$0
- Rex FosterLawrenceville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.